In our research, the factors associated with a worse outcome of tocilizumab in terms of mortality were: baseline status at initiation of tocilizumab treatment requiring IMV, elevated ferritin, LDH and GPT, lymphopenia, and low PaFi [ratio of arterial oxygen pressure to inspired oxygen fraction (PaO2/FIO2)] values. Here, GPT is linked to lymphopenia.